Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

omipalisib (GSK2126458)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

GSK

Drug class:

mTOR inhibitor, PI3K inhibitor

Related drugs:

‹

everolimus (138)

temsirolimus (37)

PF-05212384 (31)

PF-04691502 (6)

niclosamide (1)

rapamycin topical (0)

ridaforolimus (0)

encapsulated rapamycin (0)

inhibitors of the PI3K/AKT/mTOR pathway (0)

albumin-bound (0)

enzastaurin (3)

BAY 1082439 (1)

›

STK11 deletion	Non Small Cell Lung Cancer	STK11 deletion	Non Small Cell Lung Cancer	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D
GNAQ Q209L	Uveal Melanoma	GNAQ Q209L	Uveal Melanoma	trametinib + GSK2126458 Sensitive: D – Preclinical trametinib + GSK2126458 Sensitive : D	trametinib + GSK2126458 Sensitive: D – Preclinical trametinib + GSK2126458 Sensitive : D
GNA11 Q209L	Uveal Melanoma	GNA11 Q209L	Uveal Melanoma	trametinib + GSK2126458 Sensitive: D – Preclinical trametinib + GSK2126458 Sensitive : D	trametinib + GSK2126458 Sensitive: D – Preclinical trametinib + GSK2126458 Sensitive : D
NOTCH1 C344fs	Squamous Cell Carcinoma of Head and Neck	NOTCH1 C344fs	Squamous Cell Carcinoma of Head and Neck	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D
NOTCH1 E694	Squamous Cell Carcinoma of Head and Neck	NOTCH1 E694	Squamous Cell Carcinoma of Head and Neck	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D
NOTCH1 G192	Squamous Cell Carcinoma of Head and Neck	NOTCH1 G192	Squamous Cell Carcinoma of Head and Neck	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D
NOTCH1 H2018fs	Squamous Cell Carcinoma of Head and Neck	NOTCH1 H2018fs	Squamous Cell Carcinoma of Head and Neck	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D
NOTCH1 Q1957	Squamous Cell Carcinoma of Head and Neck	NOTCH1 Q1957	Squamous Cell Carcinoma of Head and Neck	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D
NOTCH1 V489fs	Squamous Cell Carcinoma of Head and Neck	NOTCH1 V489fs	Squamous Cell Carcinoma of Head and Neck	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D
NOTCH1 C478F	Squamous Cell Carcinoma of Head and Neck	NOTCH1 C478F	Squamous Cell Carcinoma of Head and Neck	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D
NOTCH1 E1679	Squamous Cell Carcinoma of Head and Neck	NOTCH1 E1679	Squamous Cell Carcinoma of Head and Neck	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D
NOTCH1 A1524V	Squamous Cell Carcinoma of Head and Neck	NOTCH1 A1524V	Squamous Cell Carcinoma of Head and Neck	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D
NOTCH1 G72R	Squamous Cell Carcinoma of Head and Neck	NOTCH1 G72R	Squamous Cell Carcinoma of Head and Neck	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D
NOTCH1 F357del	Squamous Cell Carcinoma of Head and Neck	NOTCH1 F357del	Squamous Cell Carcinoma of Head and Neck	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D
GNAQ Q209P	Uveal Melanoma	GNAQ Q209P	Uveal Melanoma	trametinib + GSK2126458 Sensitive: D – Preclinical trametinib + GSK2126458 Sensitive : D	trametinib + GSK2126458 Sensitive: D – Preclinical trametinib + GSK2126458 Sensitive : D
NRAS mutation	Melanoma	NRAS mutation	Melanoma	trametinib + GSK2126458 Sensitive: D – Preclinical trametinib + GSK2126458 Sensitive : D	trametinib + GSK2126458 Sensitive: D – Preclinical trametinib + GSK2126458 Sensitive : D
EGFR wild-type	Lung Adenocarcinoma	EGFR wild-type	Lung Adenocarcinoma	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D